AG0307OS/TROG08.07 - DECO - TROG Cancer Research

By w.paterson
15 August, 2021
0 Comments

"The DECO Study: A Randomised Phase II Trial of Weekly Docetaxel (Taxotere) Chemoradiotherapy +/- Cetuximab (Erbitux) in the Treatment of Localised Resectable Cancer of the Oesophagus."

Primary Sponsor

Tour de Cure grants for TROG Cancer Research trials

9 January, 2025

Tour de Cure grants support two valuable TROG trials

9 January 2025: Two important TROG Cancer Research trials

7 January, 2025

GenesisCare Foundation $300,000 donation to support TROG work

7 January 2025: TROG Cancer Research is advancing vital

Earlybird registration closes 26 January.

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

"The DECO Study: A Randomised Phase II Trial of Weekly Docetaxel (Taxotere) Chemoradiotherapy +/- Cetuximab (Erbitux) in the Treatment of Localised Resectable Cancer of the Oesophagus."

MRC LU24/TROG 07.02 – QUARTZ

TROG 04.02 – Cervical – FIGO Stage & Tumour Volume

Related Post

Tour de Cure grants support two valuable TROG trials

GenesisCare Foundation $300,000 donation to support TROG work

AG0307OS/TROG08.07 – DECO

"The DECO Study: A Randomised Phase II Trial of Weekly Docetaxel (Taxotere) Chemoradiotherapy +/- Cetuximab (Erbitux) in the Treatment of Localised Resectable Cancer of the Oesophagus."

MRC LU24/TROG 07.02 – QUARTZ

TROG 04.02 – Cervical – FIGO Stage & Tumour Volume

Related Post

Tour de Cure grants support two valuable TROG trials

GenesisCare Foundation $300,000 donation to support TROG work